- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.08. | Tarsus joins Stargardt race to market with $800m Alkeus takeover | ||
| 07.08. | Context drops bispecific T-cell engager on cost-cutting initiative | ||
| 07.08. | Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations | ||
| 07.08. | Evotec and Odyssey collaborate on AI-enabled R&D | ||
| 07.08. | Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments | ||
| 06.08. | Takeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead | ||
| 06.08. | Eli Lilly raises 2026 outlook again as Q2 soars past estimates | ||
| 06.08. | Alteogen signs $365m Hybrozyme licensing deal with pharma company | ||
| 06.08. | Schrödinger and BMS expand partnership to deploy AI for drug discovery | ||
| 05.08. | Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says | ||
| 05.08. | What is 'Premium Content' on Pharmaceutical Technology? | ||
| 05.08. | Mironid banks $46m in Series B to take rare kidney disease drug closer to clinic | ||
| 05.08. | AsymBio to secure $184m to support growth in biologics manufacturing | ||
| 05.08. | Phylo and Chugai collaborate to deploy AI platform in drug discovery | ||
| 04.08. | Pfizer repels Covid-19 sales tumble to raise 2026 guidance | ||
| 04.08. | Supernus and Indivior merge to create scaled, CNS-focused entity | ||
| 04.08. | FDA grants breakthrough therapy designation to Lilly's olomorasib | ||
| 04.08. | Curium to acquire Lantheus in all-cash deal worth up to $8bn | ||
| 03.08. | Amgen contends with data breach, exposing patient information | ||
| 03.08. | AstraZeneca shares slump after $400bn BMS merger rumours | ||
| 03.08. | IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib | ||
| 03.08. | Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy | ||
| 31.07. | Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns | ||
| 31.07. | J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout | ||
| 31.07. | miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.